Global Chronic Kidney Disease (CKD) Drugs Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2017 to 2025

  • ID: 4313384
  • Report
  • Region: Global
  • Acute Market Reports
1 of 4

FEATURED COMPANIES

  • AbbVie, Inc.
  • Allergan plc.
  • Amgen Inc.
  • AstraZeneca plc.
  • F. Hoffmann-La Roche Ltd
  • FibroGen
  • MORE
Chronic Kidney Disease (CKD) Drugs Market - Growth, Future Prospects and Competitive Analysis, 2017 - 2025 the global Chronic Kidney Disease (CKD) Drugs market was valued at US$ 12.4 Bn in 2016, and is expected to reach US$ 17.4 Bn by 2025, expanding at a CAGR of 3.9% from 2017 to 2025.

Market Insights
Chronic Kidney Disease (CKD) is also known as chronic kidney failure characterized by gradual loss of kidney function. There are different types of medications available in market. Medicines cannot reverse CKD, however they are used to treat complications and to slow further kidney damage. Factors such as rising incidence of cardiovascular disorders and diabetes, increasing geriatric population, significant unmet needs, promising pipeline molecule such as ABT-614 (Abbott laboratories), EOS789 (Chugai Pharmaceutical) and increasing prevalence of CKD would further drive the growth of CKD drugs market globally. However, preferable use of generic drugs and in some countries may negatively impacting the market growth. For the purpose of study, global chronic kidney disease (CKD) drugs market is categorized on the basis of drug class such as antihypertensive, antihyperlipidemic, anemia treatment medications, swelling and other treatment medications. It is observed that, in the base year 2016, antihypertensive held largest market share because high blood pressure is major complication associated with CKD. Currently, CKD drugs market is dominated by North America, due to factors such as higher cost of medication, changing healthcare reimbursement environment and upsurge in funding by government agencies and private organizations in healthcare system driving the growth of CKD drugs market in North America. It is estimated that Asia Pacific will grow at fastest CAGR during forecast period due to the factors such as increasing incidence of diabetes and hypertension, continues development in economic conditions, increase in health care spending, populous countries and developing healthcare infrastructure would drive market growth in Asia Pacific during forecast period.

Market Competition Assessment:
The Chronic Kidney Disease (CKD) Drugs market is observed to be highly competitive and comprises large number of players. However, the market is currently dominated by few players such as AbbVie, Inc., Allergan plc. Amgen Inc., AstraZeneca plc., F. Hoffmann-La Roche Ltd, FibroGen, GlaxoSmithKline plc., Johnson & Johnson, Keryx Biopharmaceuticals, Inc., Kissei Pharmaceutical Co. Ltd., Pfizer, Inc., Sanofi S.A., Teva Pharmaceutical Industries Ltd. and other.

Key Market Movements:
  • Factors such as rising incidence of CKD, increasing geriatric population, favorable reimbursement policies in some countries and high degree of R&D activity in development of CKD drugs are driving the market growth globally.
  • Due to the high unmet needs, manufacturers in the market are focusing on innovation and technological advances in treatment, this would further influence the market growth of CKD drugs globally.
  • However, poor patient compliance in some countries and preferable use of generic drugs would negatively impact market growth of CKD Drugs.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AbbVie, Inc.
  • Allergan plc.
  • Amgen Inc.
  • AstraZeneca plc.
  • F. Hoffmann-La Roche Ltd
  • FibroGen
  • MORE
Chapter 1 Preface
1.1 Report Description
1.1.1 Purpose of the Report
1.1.2 Target Audience
1.1.3 Usp and Key Offerings
1.2 Research Scope
1.3 Research Methodology
1.3.1 Phase I - Secondary Research
1.3.2 Phase II - Primary Research
1.3.3 Phase III - Expert Panel Review
1.3.4 Assumptions

Chapter 2 Executive Summary
2.1 Global Chronic Kidney Disease (Ckd) Drugs Market Snapshot
2.2 Global Chronic Kidney Disease (Ckd) Drugs Market, by Drug Class, 2016 (US$ Bn)
2.3 Global Chronic Kidney Disease (Ckd) Drugs Market Share, by Geography, 2016 (Value %)

Chapter 3 Chronic Kidney Disease (Ckd) Drugs Market Analysis
3.1 Global Chronic Kidney Disease (Ckd) Drugs Market Overview
3.2 Market Dynamics
3.2.1 Market Drivers
3.2.1.1 High Prevalence of Chronic Kidney Disease (Ckd)
3.2.2 Challenges
3.2.3 Opportunities
3.3 Attractive Investment Proposition
3.4 Competitive Landscape of Key Players in Chronic Kidney Disease (Ckd) Drugs Market

Chapter 4 Global Chronic Kidney Disease (Ckd) Drugs Market, by Drug Class
4.1 Overview
4.2 Antihypertensive
4.3 Antihyperlipidemic
4.4 Anemia Treatment Drugs
4.5 Swelling Treatment Drugs
4.6 Other

Chapter 5 Global Chronic Kidney Disease (Ckd) Drugs Market, by Geography
5.1 Preface
5.2 North America (U.S. & Canada)
5.3 Europe (U.K., Germany & Rest of Europe)
5.4 Asia Pacific (China, Japan and Rest of Apac)
5.5 Latin America
5.6 Middle East and Africa

Chapter 6 Company Profiles
6.1 Abbvie, Inc
6.2 Allergan Plc
6.3 Amgen Inc
6.4 Astrazeneca Plc
6.5 F. Hoffmann-La Roche Ltd
6.6 Fibrogen
6.7 Glaxosmithkline Plc
6.8 Johnson & Johnson
6.9 Keryx Biopharmaceuticals, Inc
6.10 Kissei Pharmaceutical Co., Ltd
6.11 Pfizer, Inc
6.12 Sanofi S.A
6.13 Teva Pharmaceutical Industries Ltd

List of Figures
Figure 1 Chronic Kidney Disease (Ckd) Drugs Market: Research Methodology
Figure 2 Global Chronic Kidney Disease (Ckd) Drugs Market, by Drug Class, 2016 (US$ Bn)
Figure 3 Global Chronic Kidney Disease (Ckd) Drugs Market Share, by Geography, 2016 (Value %)
Figure 4 Attractive Investment Proposition: Global Chronic Kidney Disease (Ckd) Drugs Market, by Geography, 2016
Figure 1 Global Antihypertensive Market for Chronic Kidney Disease (Ckd) Drugs, 2015 - 2025 (US$ Bn)
Figure 1 Global Antihyperlipidemic Market for Chronic Kidney Disease (Ckd) Drugs, 2015 - 2025 (US$ Bn)
Figure 1 Global Anemia Treatment Drugs Market for Chronic Kidney Disease (Ckd) Drugs, 2015 - 2025 (US$ Bn)
Figure 1 Global Swelling Treatment Drugs Market for Chronic Kidney Disease (Ckd) Drugs, 2015 - 2025 (US$ Bn)
Figure 1 Global Other Medication Market for Chronic Kidney Disease (Ckd) Drugs, 2015 - 2025 (US$ Bn)
Figure 2 Latin America Chronic Kidney Disease (Ckd) Drugs Market, 2015 - 2025 (US$ Bn)
Figure 3 Middle East and Africa Chronic Kidney Disease (Ckd) Drugs Market, 2015 - 2025 (US$ Bn)

List of Tables
Table 1 Market Positioning of Key Players in Global Chronic Kidney Disease (Ckd) Drugs Market
Table 2 Global Chronic Kidney Disease (Ckd) Drugs Market, by Drug Class, 2015 - 2025 (US$ Bn)
Table 3 Global Chronic Kidney Disease (Ckd) Drugs Market, by Geography, 2015 - 2025 (US$ Bn)
Table 4 North America Chronic Kidney Disease (Ckd) Drugs Market, 2015 - 2025 (US$ Bn)
Table 5 Europe Chronic Kidney Disease (Ckd) Drugs Market, 2015 - 2025 (US$ Bn)
Table 6 Asia Pacific Chronic Kidney Disease (Ckd) Drugs Market, 2015 - 2025 (US$ Bn)
Table 7 Abbvie, Inc
: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
Table 8 Allergan Plc.: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
Table 9 Amgen Inc.: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
Table 10 Astrazeneca Plc.: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
Table 11 F. Hoffmann-La Roche Ltd: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
Table 12 Fibrogen: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
Table 13 Glaxosmithkline Plc.: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
Table 14 Johnson & Johnson: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
Table 15 Keryx Biopharmaceuticals, Inc.: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
Table 16 Kissei Pharmaceutical Co., Ltd: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
Table 17 Pfizer, Inc.: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
Table 18 Sanofi S.A.: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
Table 19 Teva Pharmaceutical Industries Ltd.: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • AbbVie, Inc.
  • Allergan plc.
  • Amgen Inc.
  • AstraZeneca plc.
  • F. Hoffmann-La Roche Ltd
  • FibroGen
  • GlaxoSmithKline plc.
  • Johnson & Johnson
  • Keryx Biopharmaceuticals, Inc.
  • Kissei Pharmaceutical Co., Ltd
  • Pfizer, Inc.
  • Sanofi S.A.
  • Teva Pharmaceutical Industries Ltd.
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll